Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-06-14, Stock:ABBV, The news for the past five days is as follows:
2019-06-07: NEWS1: Zacks.com featured highlights include: HP, Party City, AbbVie, OncoSec Medical and Pulmatrix.NEWS2: Zacks.com featured highlights include: HP, Party City, AbbVie, OncoSec Medical and Pulmatrix.NEWS3: AstraZeneca's Calquence Meets Endpoint in 2nd CLL Study.NEWS4: AstraZeneca's Calquence Meets Endpoint in 2nd CLL Study.NEWS5: iShares Core Dividend Growth ETF Experiences Big Inflow.NEWS6: iShares Core Dividend Growth ETF Experiences Big Inflow.NEWS7: AstraZeneca's Calquence Meets Endpoint in 2nd CLL Study.NEWS8: Zacks.com featured highlights include: HP, Party City, AbbVie, OncoSec Medical and Pulmatrix.NEWS9: Why I'm Sticking With My 3 Worst-Performing Stocks of 2019 So Far.NEWS10: Why I'm Sticking With My 3 Worst-Performing Stocks of 2019 So Far.NEWS11: AbbVie to Present at the Goldman Sachs Global Healthcare Conference.NEWS12: Why I&apos;m Sticking With My 3 Worst-Performing Stocks of 2019 So Far.
2019-06-10: NEWS1: AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know.NEWS2: Top Ranked Growth Stocks to Buy for June 10th.NEWS3: See what the IHS Markit Score report has to say about AbbVie Inc..NEWS4: AbbVie's MAVIRET™ now listed on the Nova Scotia and Manitoba formularies.NEWS5: Better Buy: Eli Lilly vs. AbbVie.NEWS6: Better Buy: Eli Lilly vs. AbbVie.
2019-06-11: NEWS1: 10 Smart Dividend Stocks for the Rest of the Year.NEWS2: Roche's Polivy Gets FDA Nod, Gazyva Meets Goals in Phase II.NEWS3: Roche's Polivy Gets FDA Nod, Gazyva Meets Goals in Phase II.NEWS4: Roche's Polivy Gets FDA Nod, Gazyva Meets Goals in Phase II.NEWS5: Lilly Announces Tradjenta Cardiovascular Outcome Study Data.NEWS6: New Two-Year Data at the 24th World Congress of Dermatology Shows SKYRIZI™ (risankizumab) Maintains Complete Skin Clearance.NEWS7: AbbVie- Unique Mix of Growth, Income  Value.NEWS8: Horseman Capital Management’s Return, AUM, and Holdings.
2019-06-12: NEWS1: New Long-Term Data from Upadacitinib Phase 3 Studies in Rheumatoid Arthritis Including Results on Clinical Remission at 48 Weeks Presented at EULAR.NEWS2: 5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit.NEWS3: 10 Smart Dividend Stocks for the Rest of the Year.NEWS4: 10 Smart Dividend Stocks for the Rest of the Year.
2019-06-13: NEWS1: Amgen, Biogen, Gilead and Novo Nordisk have ‘very high’ capacity for M&A, says Moody’s.NEWS2: Pfizer's (PFE) Xeljanz Effective As Monotherapy in RA Study.NEWS3: Pfizer's (PFE) Xeljanz Effective As Monotherapy in RA Study.NEWS4: Pfizer's (PFE) Xeljanz Effective As Monotherapy in RA Study.

Answer: Decrease